An impressive contract was signed in the Castilian-Leonese health system. The Government presided by Alfonso Fernández Mañueco has resolved a $79 million (€70 million) tender to provide hospitals and health centers in the public regional network with injectable and tablet medicines, as can be seen from the profile of the regional contractor.
The contract in question is expected to last one year and is divided into 23 different lots, which have been awarded to different pharmaceutical companies. Among the winners and those who have won a large part of the contract are Janssen, Merck, Novartis and Roche. The centers to which these drugs are directed are the Complejo Asistencial de Ávila, the Complejo Asistencial de Burgos, the Hospital Santiago Apóstol de Miranda de Ebro, the Hospital Santos Reyes de Aranda de Duero and the Hospital Clínico Universitario de Valladolid, among others.
Find out more details about the massive contract resolved by the Government to the health sector in Spain and be the first to find the most important business news with our companion app, Born2Invest.
Janssen will supply its Ustekinumab product, indicated for the treatment of adult patients with ulcerative colitis
The largest amount corresponds to the Johnson&Johnson group’s pharmacist, Janssen, which will supply its Ustekinumab product, indicated for the treatment of adult patients with ulcerative colitis, for a total of $13.2 million (€11.7 million).
The company will also provide hospitals in Castilla y León with Etravirina, an antiviral drug used for the treatment of infection caused by the human immunodeficiency virus (HIV), the agent that causes AIDS, and will do so for more than $452,000 (€400,000).
Novartis is also one of the big winners of this competition
The Swiss multinational has been awarded the supply of Fingolimod, an immunomodulator used in the treatment of multiple sclerosis, for $9.2 million (€8.2 million). This company has also been awarded another lot, for $7.1 million (€6.3 million), for the distribution of Ranibizumab, also known as Lucentis. That is a pharmacological therapy approved to improve vision and quality of life in patients with visual impairment due to diabetic macular edema (DME).
Novartis will also provide the Castilla y León Health Service (Sacyl) with a total of $3.4 million (€3 million) for its drug Nilotinib, a small molecule of the tyrosine kinase inhibitor that is approved for treating chronic myelogenous leukaemia.
The only company of Spanish origin that is involved in this contract is PharmaMar
Merck has also been selected. The pharmaceutical company will provide hospitals in the Cetuximab region with over $3.4 million (€3 million). This drug is used to treat colon cancer and other types of squamous cell cancer that affect the head and neck, such as some tumors of the mouth or larynx. It is applied weekly and is given intravenously.
In addition to these multinational pharmaceutical companies, this contract also includes Biogen España, Japan’s Takeda and Spain’s PharmaMar. PharmaMar will supply Yondelis (trabectedin), a marine-based antitumor compound, for $1.7 million (€1.5 million).
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Jazz Pharmaceuticals’ Leukemia Drug Receives European Commission Approval
Jazz Pharmaceuticals is a biopharmaceutical company dedicated to the development of drugs in neuroscience and oncology. Founded in 2003 in...
Citi Announced a $6 Million Loan to Sempli for SME financing
The credit granted by Citi was given in partnership with high-impact investors and multilateral development organizations. They all seek to...
How Will the Price of Ripple and Cardano Develop in the Next Few Days
The BOLL indicator shows no specific pattern and denotes the support price of $0.4969 and the resistance price of $0.5059,...
RADEEF: a 182 Million Dirham Plan to Combat Flooding in Morocco
RADEEF is also planning major expansion projects. Firstly, it plans to launch work on extending the wastewater treatment plant. The...
How Institutional Investors Feel About Impact Investing
Investors continue to face greenwashing when implementing impact investing. Among their key concerns are misleading or exaggerated impact claims (60%),...
Biotech1 week ago
AbolerIS Pharma Closes a Round of €27 Million Led by Caixa Capital
Business3 days ago
Current Woes in Bonds Promise Future Grief for Stocks: Focus on Dow Jones
Crypto2 weeks ago
BitBoy Crypto Ends Partnership with Youtuber Ben Armstrong
Business1 week ago
Your Small Business Phone Is Scaring Away 94% of Your Clients. Here’s How to Fix it With Air Landline